ow dose magnesium sulphate for treatment of seizures in pregnancy

Phase 3

• Conditions: Health Condition 1: O159- Eclampsia, unspecified as to timeperiod

• Registration Number: CTRI/2021/08/035456
• Lead Sponsor: World Health Organization

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Closed to Recruitment of Participants
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Women meeting all of the following criteria:

1. Be admitted with a diagnosis of pre-eclampsia and with clinical or laboratory indication(s) for magnesium sulfate treatment, as defined by any of the following: two readings of systolic blood pressure more than or equal to 160 mm Hg, or diastolic blood pressure more than or equal to 110 mm Hg along with more than or equal to 2+ proteinuria on urine dipstick; or the presence of symptoms, signs or laboratory findings suggestive of severe disease such as headache, visual disturbances, upper abdominal pain, pulmonary oedema, nausea and vomiting, hyperreflexia or clonus, elevated liver enzymes, raised serum creatinine, or thrombocytopenia. Women with HELLP syndrome, a severe form of pre-eclampsia characterized by Haemolysis, Elevated Liver enzymes, and Low Platelets (less than 100 cells per mcl) will be included if there is no clinical contraindication to IM injection.

2. Have not yet given birth but birth is planned or expected within the next 24 hours, or have given birth within the last 24 hours.

3. Provide written informed consent before any trial-related procedures are carried out

Exclusion Criteria

Women are not eligible if they fulfill any of the following exclusion criteria:

1. Unable or unwilling to give informed consent (because the woman is too distressed or not capable to understand, confirm and give informed consent due to emergency or health condition, or does not wish to be randomized for whatever reason).

2. Less than 18 years of age.

3. History of hypersensitivity to magnesium sulfate.

4. Serious cardiovascular disorders (WHO classification III or IV or acute heart failure).

5. Serious hepatic (encephalopathy or coma) or renal disease.

6. History of epilepsy.

7. Myasthenia gravis or any muscular dystrophies.

8. Coagulopathy.

9. Have previously received magnesium sulfate for eclampsia prevention in the current pregnancy.

10. Planned to receive magnesium sulfate regimen other than the regimens specified for the trial on account of other medical indication(s) (e.g. fetal neuroprotection).

11. Known oliguria (less than 400mL urine in 24 hours) at the time of admission.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Maternal eclamptic seizure (defined as occurrence of convulsions in a woman with features of pre-eclampsia that is unrelated to other neurological conditions)Timepoint: until the time of hospital discharge or transfer to a higher care unit or death